Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBX 200
- Development stage
- Preclinical
- Lead developer
- Cellbricks Therapeutics
- Modality
- Cell Therapies
- Administration
- Surgical Implantation
01
Overview
CBX 200 is a tissue-engineered liver therapeutic being developed by Cellbricks Therapeutics for the treatment of chronic liver disease. Developed using proprietary 3D bioprinting technology, CBX 200 is designed as a functional liver tissue construct intended to restore or supplement metabolic and synthetic liver functions in patients with chronic hepatic failure. The program aims to create complex, vascularized tissue architectures that can integrate with the host system to provide functional support, potentially serving as a bridge to transplantation or a long-term therapeutic alternative. As of early 2024, the program is in the discovery stage of development.
Beyond the preview
Go deeper on CBX 200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBX 200.